Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

SML2844

Sigma-Aldrich

Rivaroxaban

≥98% (HPLC)

Synonyme(s) :

(S)-Rivaroxaban, (S)-5-Chloro-N-{[2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyl} thiophene-2-carboxamide, 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, BAY 59-7939, BAY-59-7939, BAY59-7939, 5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C19H18ClN3O5S
Numéro CAS:
366789-02-8
Poids moléculaire :
435.88
Numéro MDL:
MFCD11974010
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Activité optique

[α]/D -34 to -44, c = 0.3 in DMSO

Couleur

white to beige

Solubilité

DMSO: 2 mg/mL, clear

Température de stockage

2-8°C

InChI

1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1

Clé InChI

KGFYHTZWPPHNLQ-AWEZNQCLSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Actions biochimiques/physiologiques

Rivaroxaban is an orally active, active site-targeting, highly potent and selective factor Xa (FXa) inhibitor (IC50 = 0.7 nM; no activity against thrombin, trypsin, plasmin, FVIIa, FIXa, FXIa, urokinase, or activated protein C up to 20 μM) with good anticoagulant activity in vitro (dose for doubling fibrin formation time = 230/300 nM in human/rat plasma) and antithrombotic efficacy in vivo (ED50 = 1 mg/kg i.v. or 5 mg/kg p.o. by rat arteriovenous shunt model).

Pictogrammes

Environment
GHS09

Mentions de danger

H411

Conseils de prudence

P273 - P391 - P501

Classification des risques

Aquatic Chronic 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.
G T Gerotziafas et al.
Journal of thrombosis and haemostasis : JTH, 5(4), 886-888 (2007-03-29)
Tobias Petzold et al.
Circulation research, 126(4), 486-500 (2019-12-21)
A reduced rate of myocardial infarction has been reported in patients with atrial fibrillation treated with FXa (factor Xa) inhibitors including rivaroxaban compared with vitamin K antagonists. At the same time, low-dose rivaroxaban has been shown to reduce mortality and
Faisal Imam et al.
Cardiovascular toxicology, 20(3), 281-290 (2019-11-07)
Sunitinib (SUN) is an oral tyrosine kinase inhibitor approved in 2006 as a first-line treatment for metastatic renal cell cancer. However, weak selectivity to kinase receptors and cardiotoxicity have limited the use of sunitinib. Rivaroxaban (RIVA) is a Factor Xa
Bart J Biemond et al.
Thrombosis and haemostasis, 97(3), 471-477 (2007-03-06)
Current anticoagulant therapies for the prevention and treatment of thromboembolic disorders have many drawbacks: vitamin K antagonists interact with food and drugs and require frequent laboratory monitoring, and heparins require parenteral administration. Oral rivaroxaban (BAY 597939) is a new, highly
C Weinz et al.
Xenobiotica; the fate of foreign compounds in biological systems, 35(9), 891-910 (2005-11-26)
The pharmacokinetics of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - were investigated in rats and dogs in support of preclinical safety studies and clinical development. BAY 59-7939 was rapidly absorbed after oral dosing, with an absolute
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique